Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GW810781 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| GW810781 | DRUG | - |
Inclusion Criteria: * No prior HIV medications. * HIV infection with viral load \>400-50,000 copies/mL. * CD4 cell count \>50 cells/mm. Exclusion Criteria: * Patients requiring medications that cannot be interrupted for the duration of the study. * Abnormal ECG or other chronic health conditions ...
Top 20 of 28 competitors
GW810781 is an investigational small molecule being studied for the treatment of HIV infections. It is not approved and remains in clinical development.
GW810781 is being developed by GSK plc, a pharmaceutical company listed on the stock exchange under the ticker GSK.
GW810781 is in Phase 2 clinical development. It has completed one Phase 2 trial and is not yet approved.
GW810781 has one completed Phase 2 trial, NCT00046332, which compared four doses of the drug versus placebo in HIV-infected patients. The trial enrolled 100 participants in the United States.
GW810781 is not FDA approved. It is an investigational drug that has completed a Phase 2 trial but remains in clinical development.